Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia

Paterlini-Bréchot P (2014) About seed and soil. Cancer Microenviron 7:91–93 Remon J, Majem M (2013) EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non-small cell lung cancer: a clue to overcoming resistance. Trans Lung Cancer Res 2:445–448 Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107–1120 Faber K, Bullinger L, Ragu C et al (2013) CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest 123:299–314 Hafner C, Toll A, Gantner S et al (2012) Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 49:249–253 Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322 Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759–3764 Pitteri SJ, Kelly-Spratt KS, Gurley KE et al (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 1:5090–5100 Bundscherer A, Hafner C (2010) Breathing new life into old drugs: Indication discovery by systems directed therapy. In: Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, pp 483–503 Pantziarka P, Bouche G, Meheus L et al (2014) The repurposing drugs in oncology (ReDO) project. Ecancer Med Sci 8:442 Papi A, De Carolis S, Bertoni S et al (2014) PPARγ and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche. J Cell Physiol 229(11):1595–1606 Glass CK, Ogawa S (2006) Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 6:44–55 Molecular cross-talk between nuclear receptors and nuclear factor-kB. Beck IME, Haegeman G, De Bosscher KA. Reichle A (ed.) From molecular to modular tumor therapy. Springer, Berlin, 191–242 Emmenegger U, Chow A, Bocci G (2010) The biomodulatory capacities of low-dose metronomic chemotherapy: Complex modulation of the tumor microenvironment. In: Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, pp 243–262 Reichle A, Hildebrandt GC (2009) Principles of modular tumor therapy. Cancer Microenviron 2(Suppl 1):227–237 Reichle A, Vogt T (2008) Systems biology: a therapeutic target for tumor therapy. Cancer Microenviron 1:159–170 Mendoza-Parra MA, Gronemeyer H (2013) Genome-wide studies of nuclear receptors in cell fate decisions. Semin Cell Dev Biol 24:706–715 Reichle A. Including rationalizations of tumor-associated normative notions in pathophysiologic considerations: Communication-theoretical implications. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 289–299 Reichle A, Gerner C, Haegeman G (2013) Criticizable claims for the validity of communication acts in biological systems: Therapeutic implications in cancer. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 169–187 Reichle A, Grassinger J, Bross K et al (2007) C-reactive protein in patients with metastatic clear cell renal carcinoma: an Important biomarker for tumor-associated Inflammation. Biomark Insights 1:87–98 Walter B, Rogenhofer S, Vogelhuber M et al (2010) Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol 28:745–750 Vogelhuber M, Feyerabend S, Stenzl A, et al. (2014) Biomodulatory treatment of patients with castration-resistant prostate cancer: A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan. Cancer Microenviron Reichle A, Hart C, Grube M et al. (2012) Anti-inflammatory, immuno-modulatory and angiostatic treatment as third-line therapy for multiple myeloma (MM)—a combined treatment setting of lenalidomide with pioglitazone, dexamethasone and low-Dose treosulfan (phase I/II) Blood (ASH Annual Meeting Abstracts) 120:5029 Thomas S, Schelker R, Klobuch S et al (2015) Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia. Haematologica 100(1):e4–e6 Ugocsai P, Wolff D, Menhart K (2015) Biomodulatory metronomic therapy induces PET negative remissionin chemo- and brentuximab-refractory Hodgkin disease. Br J Haematol. doi:10.1111/bjh.13480 Reichle A, Vogt T, Kunz-Schughart L et al (2005) Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans’ cell histiocytosis of adults. Br J Haematol 128:730–732 Reichle A, Vogelhuber M, Vogt T et al. (2013) Long-term results of combined modularized, immune-modulatory, angiostatic, and antiinflammatory therapy in systemically pre-treated multi-systems Langerhans cell histiocytosis. Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 35–45 Pahler JC, Tazzyman S, Erez N et al (2008) Plasticity in tumor promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 10:329–340 Vogt T, Coras B, Hafner C et al (2006) Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes. Lancet Oncol 7:695–697 Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892 Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. Science 339:1546–1558 Tilg H, Vogel W, Dinarello CA (1995) Interferon-alpha induces circulating tumor necrosis factor receptor p55 in humans. Blood 85:433–435 Inoue K, Kawahito Y, Tsubouchi Y et al (2001) Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem Biophys Res Commun 287:727–732 Gerber SA, Pober JS (2008) IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells. J Immunol 181:1052–1062 Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245 Pleyer L, Burgstaller S, Girschikofsky M et al (2014) Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93:1825–1838 Luatti S, Castagnetti F, Marzocchi G et al (2012) Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 120:761–767 Yeung WWS, Ho MKC, Wong YH (2010) Functional Impacts of Signal Integration: Regulation of inflammation-related transcription factors by heterotrimeric G proteins. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 161–189 Almendro V, Kim HJ, Cheng YK et al (2014) Genetic and phenotypic diversity in breast tumor metastases. Cancer Res 74:1338–1348 Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892 Yegnasubramanian S, Haffner MC, Zhang Y et al (2008) DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68:8954–8967 Galluzzi L, Vacchelli E, Bravo-San Pedro JM et al (2014) Classification of current anticancer immunotherapies. Oncotarget 5:12472–12508 Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71:1263–1271 Giraldo NA, Becht E, Remark R et al (2014) The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 27:8–15 Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964s Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319 Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:471–494 Reichle A and Hildebrandt GC (2010) The comparative uncovering of tumor systems biology by modularly targeting tumor-associated inflammation. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 287–303 Khandelwal N, Breinig M, Speck T et al (2015) A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes. EMBO Mol Med 7:450–463 Reichle A (ed) (2013) Evolution adjusted tumor pathophysiology. Springer, Berlin Reichle A. Biomodulatory therapy approaches in renal clear cell carcinoma: A perspective (2013) Reichle A (ed) Evolution-adjusted tumor pathophysiology. Springer, Berlin, 91–100 Reichle A, Vogt T, Coras B et al (2007) Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. Melanoma Res 17:360–364 Meyer S, Vogt T, Landthaler M (2009) Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. PPAR Res 2009:848645 Krug U, Koschmieder A, Schwammbach D et al (2012) Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study. PLoS ONE 7:e52695 Schlenk RF, Fröhling S, Hartmann F et al (2004) Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 18:1798–1803 Hartwell LH, Hopfield JJ, Leibler S et al (1999) From molecular to modular cell biology. Nature 402(6761 Suppl):C47–C52 Reichle A, Hildebrandt GC (2010) Uncovering tumor systems biology by biomodulatory therapy strategies. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 287–303 Paulitschke V, Kunstfeld R, Gerner C. Secretome proteomics, a novel tool for biomarkers discovery and for guiding biomodulatory therapy approaches. Reichle A (ed) From molecular to modular tumor therapy. Springer, Berlin, 405–431